https://www.selleckchem.com/products/lxh254.html Prior opioid discontinuation studies have focused on one of two characteristics of opioid prescribing, its duration (long term vs not) or dosage (high vs low). Questions remain about the experience of patients with high-dose, long-term opioid therapy (HLOT) prescriptions who are likely to be at the highest risk for adverse events. We address the following questions among the Veterans Health Administration (VHA) patients receiving HLOT 1),How has the prevalence of discontinuation of opioids changed over time?2),How do patient characteristics vary between those who do and do not discontinue? And3), how does the prevalence of discontinuation vary geographically? A retrospective observational study of VHA patients with HLOT between fiscal year (FY) 2014 and FY2018. We identified 1,281,330 patients from VHA outpatient opioid prescription data with at least a 1-day opioid supply between FY2014 and FY2018. We identified and excluded those receiving palliative care or diagnosed with metastatic cancer. For a increased. Further research is needed to understand the process by which patients are discontinued and to assess the relationship between discontinuation and health outcomes.Interventions and research to address the US opioid crisis have, for the most part, targeted opioid use, misuse, and addiction specifically. While such a focus can lead to useful innovations in the care of opioid use disorder, the fact that many persons with opioid use disorder use multiple substances (both over their life course and simultaneously in drug-using episodes) makes it imperative to address broader issues of addiction in persons who have opioid use disorder as their presenting concern. Because of integrated care and the ability to target multiple clinical concerns in parallel, the Veterans Administration (VA) may be uniquely situated to address the key issue of multi-morbidity that persons with opioid use disorder so frequently exhibit. Res